In-licensing and Other Research and Development Agreements (Details) - USD ($) $ in Millions |
3 Months Ended | 9 Months Ended | ||||
|---|---|---|---|---|---|---|
Sep. 30, 2026 |
Sep. 30, 2025 |
Mar. 31, 2025 |
Sep. 30, 2026 |
Sep. 30, 2025 |
Apr. 30, 2016 |
|
| Bayer | License and services revenue | ||||||
| Research and Development Arrangement, Contract to Perform for Others [Line Items] | ||||||
| Contract with customer, liability, change in timeframe, performance obligation satisfied, revenue recognized | $ 75.0 | $ 75.0 | ||||
| Eidos | Stanford License Agreement | ||||||
| Research and Development Arrangement, Contract to Perform for Others [Line Items] | ||||||
| Milestone payments | $ 1.0 | |||||
| Non-royalty revenue, percentage of revenue from sublicensees, term | 3 years | |||||
| Royalties on net product revenue | $ 8.4 | 1.9 | $ 17.0 | $ 3.6 | ||
| License fees | $ 4.5 | $ 0.0 | $ 4.5 | $ 6.9 | ||